siRNA therapy reduces triglycerides in patients with uncommon problem

.ANALYSIS HIGHLIGHT.19 September 2024.

Plozasiran minimized triglyceride levels through 80% and reduced the threat of pancreatitis in clients with consistent chylomicronemia, along with or even without a hereditary medical diagnosis.